144412-50-0
Chemical Structure
Lamifiban TFA
- CAS No.: 144412-50-0
- Formula:C26H29F3N4O8
- Molecular Weight:582.53
IUPAC Name: 2,2,2-trifluoroacetic acid compound with 2-((1-((4-carbamimidoylbenzoyl)-L-tyrosyl)piperidin-4-yl)oxy)acetic acid (1:1)
InChIKey: CUEOPXPXIBCIAX-BDQAORGHSA-N
SMILES: OC(C(F)(F)F)=O.O=C(N1CCC(CC1)OCC(O)=O)[C@@H](NC(C2=CC=C(C=C2)C(N)=N)=O)CC3=CC=C(C=C3)O
Biological Activity: Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lamifiban TFA | Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Moliterno DJ, et al. Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study. J Thromb Thrombolysis. 1995;2(3):165-169. [Content Brief]
Keywords
